The past decade has seen the emergence of autologous serum eye drops as a valuable tool in the armamentarium of the ocular surface specialist. These have typically been employed when all else has failed and have proven their worth in the management of severe dry eye, chemical injuries, neurotropic keratopathy, and persistent epithelial defect. In this edition of IOVS, Oh and collegues 1 give us a glimpse of what could be the next generation of biologic eye drop therapy for severe ocular surface disease: eye drops derived from human mesenchymal stem cell (hMSC)-conditioned medium.
